IVA vs AKBA vs KO vs FOLD vs HALO

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -47. 4% for Inventiva S. A. (IVA). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 27. 1x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Inventiva S. A. (IVA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 27. 1x versus The Coca-Cola Company at 27. 2x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 37x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -75. 2% for Inventiva S. A. (IVA). Over 10 years, the gap is even starker: HALO returned +701. 6% versus AKBA's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Inventiva S. A. 's 1. 59β — meaning IVA is approximately -893% more volatile than KO relative to the S&P 500. On balance sheet safety, The Coca-Cola Company (KO) carries a lower debt/equity ratio of 133% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus -47. 4% for Inventiva S. A. (IVA). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -45. 7% for Inventiva S. A.. Over a 3-year CAGR, IVA leads at 29. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -20. 0% for Inventiva S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -1060. 6% for IVA. At the gross margin level — before operating expenses — IVA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 37x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 6x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 32. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 332. 7% to $4. 00.

In this comparison, KO (2.

5% yield) pays a dividend. IVA, AKBA, FOLD, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Inventiva S. A. (IVA) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, IVA: -71. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IVA (Healthcare) and AKBA (Healthcare) and KO (Consumer Defensive) and FOLD (Healthcare) and HALO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IVA is a small-cap quality compounder stock; AKBA is a small-cap high-growth stock; KO is a large-cap quality compounder stock; FOLD is a small-cap high-growth stock; HALO is a small-cap high-growth stock. KO pays a dividend while IVA, AKBA, FOLD, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.